Maxime Verhoeven

247 List of publications VerhoevenMMA , Tekstra J, van Laar JM, Pethö-SchrammA, BormMEA, Bijlsma JWJ, Jacobs JWG, Lafeber FPJG, Welsing PMJ. Effect on costs and quality-adjusted life-years of treat-to- target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. J Rheumatol . 2020 August [Epub ahead of print] VerhoevenMMA , Tekstra J, Welsing PMJ, Pethö-Schramm A, BormMEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. Rheumatology . 2020;59:2325-2333 Verhoeven MMA , de Hair MJH, Tekstra J, Bijlsma JWJ, van Laar JM, Pethö-Schramm A, Borm MEA, ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FPJG, Jacobs JWG, Welsing PMJ. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis . 2019;78:1333-1338 Besselink NJ, Westgeest AAA, Klaasen R, Gamala M, van Woerkom JM, Tekstra J, Verhoeven MMA , van Spil WE, Lafeber FPJG, Marijnissen ACA, van Laar JM, Jacobs JWG. Novel optical spectral (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early RA. Trials . 2019;20:226 Verhoeven MMA , Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG. Effectiveness of remission induction strategies for early rheumatoid arthritis: a systematic literature review. Curr Rheumatol Rep . 2019;21:24 Obeid R, Heil SG, Verhoeven MMA , van den Heuvel EGHM, de Groot LCPGM, Eussen SJPM. Vitamine B12 intake from animal foods, biomakers, and health aspects. Front. Nutr. 2019;6:93